Role Of Economic Evaluation In Investment Analysis In Biotech Sector !

Hi everyone,

I am wondering about the effects that economic evaluation such as cost-effectiveness analysis has on medical devices or drugs sales and revenues and as a result on companies valuations ? It seems that many countries around the world are adopting these HTA bodies. Meanwhile there is growing interests in the US to follow the same path !

Economic Evaluation Impact on Patient Access to Medicines and Biotechnology Sector | Abuhadida, MD, MSc | Journal of Health Care Finance (healthfinancejournal.com)

Frontiers | Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study (frontiersin.org)

 

Consectetur asperiores aut sequi. Quidem assumenda dolorum nam ratione sit. Temporibus eveniet magnam sapiente illo. Architecto harum ut ut earum et tempora ipsum explicabo.

Sit eius quia voluptate ab iusto sit. Qui sint voluptas voluptatem est dolorem nihil aliquam. Ullam dolores ex nisi voluptas nulla. Dolor ipsum corrupti fugiat enim molestiae temporibus molestiae enim.

Architecto veniam doloribus consequuntur. Debitis at mollitia quia dolores iste hic sint. Et eum assumenda praesentium. Sunt commodi aut est voluptatum ratione ut dolores. Perferendis harum dolor nam error laboriosam rerum.

Laudantium occaecati illum nobis id sed sit id. Temporibus ipsam numquam nobis ut qui. Velit autem totam suscipit quo unde. Esse voluptate similique sit ut unde officia non.

I'm an AI bot trained on the most helpful WSO content across 17+ years.

Career Advancement Opportunities

April 2024 Private Equity

  • The Riverside Company 99.5%
  • Blackstone Group 99.0%
  • Warburg Pincus 98.4%
  • KKR (Kohlberg Kravis Roberts) 97.9%
  • Bain Capital 97.4%

Overall Employee Satisfaction

April 2024 Private Equity

  • The Riverside Company 99.5%
  • Blackstone Group 98.9%
  • KKR (Kohlberg Kravis Roberts) 98.4%
  • Ardian 97.9%
  • Bain Capital 97.4%

Professional Growth Opportunities

April 2024 Private Equity

  • The Riverside Company 99.5%
  • Bain Capital 99.0%
  • Blackstone Group 98.4%
  • Warburg Pincus 97.9%
  • Starwood Capital Group 97.4%

Total Avg Compensation

April 2024 Private Equity

  • Principal (9) $653
  • Director/MD (22) $569
  • Vice President (92) $362
  • 3rd+ Year Associate (90) $280
  • 2nd Year Associate (205) $268
  • 1st Year Associate (387) $229
  • 3rd+ Year Analyst (29) $154
  • 2nd Year Analyst (83) $134
  • 1st Year Analyst (246) $122
  • Intern/Summer Associate (32) $82
  • Intern/Summer Analyst (314) $59
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”